Cancer Drug Manufacturers Sue HHS OIG Over Denial Of Part D Patient Assistance Program
Executive Summary
Complaint against the US government watchdog agency disputes its conclusion that a proposed cost sharing assistance program in Medicare to be funded by a coalition of cancer drug manufacturers would likely violate the federal anti-kickback statute.
You may also be interested in...
Cancer Rx Assistance Program Proposed For Part D Fails In Court As OIG Win Streak Continues
Defeat for group covering about 50 drugs from various sponsors is in line with an earlier court battle fought, and lost, by Pfizer and means the OIG will continue to scrutinize cost sharing assistance programs with a narrow view of what comports with the federal Anti-Kickback Statute.
Pfizer Case May Be ‘Only Chance’ For Supreme Court To Save Co-Pay Charity Assistance Programs
Based on HHS’ interpretation of the Anti-Kickback Statute, 11 pharma companies, including Pfizer, have reached settlements on their programs offering financial assistance to Medicare patients trying to access treatment. Now the firm hopes its tafamidis program will help it win in court.
Cost Sharing Program In Part D From Coalition Of Cancer Drug Manufacturers Rebuffed By OIG
Federal watchdog group acknowledges proposed assistance program aligns with comments in a 2005 OIG advisory bulletin on patient assistance programs in Medicare Part D, but maintains the bulletin should not serve as a roadmap for a compliant program in this case.